Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) – SunTrust Banks increased their Q1 2018 EPS estimates for shares of Bellicum Pharmaceuticals in a report released on Tuesday, March 13th, according to Zacks Investment Research. SunTrust Banks analyst P. Lawson now forecasts that the biopharmaceutical company will post earnings per share of ($0.79) for the quarter, up from their previous forecast of ($0.80). SunTrust Banks has a “Buy” rating and a $18.00 price objective on the stock. SunTrust Banks also issued estimates for Bellicum Pharmaceuticals’ FY2019 earnings at ($3.03) EPS, FY2020 earnings at ($2.84) EPS, FY2021 earnings at $0.14 EPS and FY2022 earnings at $0.49 EPS.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.08. The firm had revenue of ($0.07) million for the quarter, compared to analyst estimates of $0.08 million.
BLCM has been the topic of a number of other research reports. Zacks Investment Research upgraded Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.00 price objective on the stock in a research note on Friday, January 19th. ValuEngine upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. Cantor Fitzgerald set a $10.00 price objective on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, February 23rd. Citigroup upped their price objective on Bellicum Pharmaceuticals from $24.00 to $27.00 and gave the stock a “hold” rating in a research note on Friday, February 16th. Finally, BidaskClub cut Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 11th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $16.88.
NASDAQ:BLCM traded down $0.27 during trading hours on Friday, reaching $6.39. 312,031 shares of the stock were exchanged, compared to its average volume of 561,094. Bellicum Pharmaceuticals has a twelve month low of $5.02 and a twelve month high of $14.49. The company has a market cap of $223.59, a P/E ratio of -2.25 and a beta of 0.47. The company has a quick ratio of 8.37, a current ratio of 8.37 and a debt-to-equity ratio of 0.41.
In related news, major shareholder Bros. Advisors Lp Baker sold 260,600 shares of the stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $8.63, for a total value of $2,248,978.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last 90 days, insiders sold 1,141,822 shares of company stock worth $9,475,583. 18.77% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Nationwide Fund Advisors raised its stake in Bellicum Pharmaceuticals by 30.4% in the 2nd quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 3,620 shares during the period. The Manufacturers Life Insurance Company raised its stake in Bellicum Pharmaceuticals by 26.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,319 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 4,684 shares during the period. New York State Common Retirement Fund raised its stake in Bellicum Pharmaceuticals by 30.8% in the 2nd quarter. New York State Common Retirement Fund now owns 28,000 shares of the biopharmaceutical company’s stock valued at $327,000 after acquiring an additional 6,599 shares during the period. California State Teachers Retirement System raised its stake in Bellicum Pharmaceuticals by 16.7% in the 2nd quarter. California State Teachers Retirement System now owns 48,146 shares of the biopharmaceutical company’s stock valued at $562,000 after acquiring an additional 6,900 shares during the period. Finally, D.A. Davidson & CO. increased its position in Bellicum Pharmaceuticals by 17.4% during the 3rd quarter. D.A. Davidson & CO. now owns 47,650 shares of the biopharmaceutical company’s stock worth $550,000 after buying an additional 7,050 shares during the period. Institutional investors and hedge funds own 54.57% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/q1-2018-earnings-estimate-for-bellicum-pharmaceuticals-inc-issued-by-suntrust-banks-blcm.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Get a free copy of the Zacks research report on Bellicum Pharmaceuticals (BLCM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.